What is the 14-day rule for lab date of service, and when does it change who bills?

Almost every page written about this rule gets one thing wrong, and it is the thing that decides who sends the bill. The 14-day rule and the molecular pathology exception are two different rules with two different tests, and only one of them has a 14-day clock in it.

What is the 14-day rule for lab date of service?

The 14-day rule is a Medicare date of service rule. The general rule at 42 CFR 414.510 is that the date of service for a clinical diagnostic laboratory test is the date the specimen was collected. The 14-day rule is one of the exceptions that moves it: for a test run on a stored specimen, the date of service becomes the date the test was performed, but only when the ordering physician placed the order at least 14 days after the patient was discharged.

Why the date matters at all: the date of service decides whether the test falls inside a hospital stay or outside it. Inside, it is bundled into what Medicare already pays the hospital. Outside, it is a separately payable laboratory test on the Clinical Laboratory Fee Schedule. The date is not an administrative field. It is the thing that routes the money.

If the specimen spans two calendar days, the date of service is the day collection ended. That single sentence resolves a surprising share of the overnight-collection arguments we see in AR queues.

Which exception are you actually in?

There are three, they sit in different paragraphs of the same regulation, and they are not interchangeable. Getting the paragraph right is most of the work.

The stored specimen exception, 414.510(b)(2)

This is the one people mean when they say 14-day rule. The date of service moves to the performance date only when all five conditions hold: the physician ordered the test at least 14 days after the patient's discharge date, the specimen was collected during a hospital surgical procedure, collecting it any other way would have been medically inappropriate, the results did not guide treatment during the hospital stay, and the test was reasonable and medically necessary for treatment of an illness.

There is a second clock inside this one that almost nobody publishes. If the specimen sits in storage more than 30 calendar days before testing, it is treated as archived, and the date of service becomes the date the specimen was taken out of storage, not the date it was collected and not the date it was run.

The chemotherapy sensitivity exception, 414.510(b)(3)

Same shape, different trigger. The 14-day count runs from the decision about which chemotherapeutic agents to use rather than from the order, the specimen has to have come from a hospital procedure, and the results must not have guided care during the stay. The regulation defines the test as one needing fresh tissue to assess how tumor cells respond to chemotherapeutic agents.

The molecular pathology and ADLT exception, 414.510(b)(5)

This is the one that carries the commercial weight, and it contains no 14-day waiting period at all. It covers a molecular pathology test performed by a laboratory other than a blood bank or blood center, a test CMS has designated an Advanced Diagnostic Laboratory Test, a cancer-related protein-based MAAA, and the test described by CPT code 81490.

Its five conditions are about a hospital outpatient encounter, not a discharge clock: the test was performed after the patient was discharged from the hospital outpatient department, the specimen was collected from a hospital outpatient during an encounter as defined at 42 CFR 410.2, it was medically appropriate to collect the specimen during that encounter, the results did not guide treatment during that encounter, and the test was reasonable and medically necessary.

Read those side by side and the drafting error in most published guidance becomes obvious. Waiting 14 days does nothing for a molecular test on an outpatient specimen, because no 14-day condition applies to it. Waiting is not a strategy there; it is just delay.

When does the 14-day rule change who bills Medicare?

When an exception applies, the test stops being a hospital service. CMS is direct about the consequence: the test is not a hospital outpatient service, and the performing laboratory must bill Medicare directly under the Clinical Laboratory Fee Schedule. When no exception applies, the hospital bills and the laboratory bills the hospital, not Medicare.

Three patient statuses, three different answers, and the status is set at registration rather than in the lab.

Hospital inpatient

The date of service lands inside the stay, so the test is bundled into the inpatient payment. The laboratory has no Medicare claim to send. The stored specimen exception is the only route out, and it requires the full five conditions including the 14-day order.

Hospital outpatient

This is where the molecular and ADLT exception lives. Meet the five conditions and the laboratory bills Medicare directly. Miss any one of them and the test belongs to the hospital encounter.

Non-patient, the referred specimen

A person who is neither an inpatient nor a registered hospital outpatient is a non-patient. The date of service exception does not apply, because there was no encounter to be discharged from. The date of service is the collection date. We see this misread constantly: a specimen arriving from an outside physician office is not a hospital outpatient specimen, and treating it as one is the fourth most common failure in our audit.

How do you build the claim when the laboratory bills directly?

Six steps. Most teams get the first four right and lose the claim on the last two.

1. Fix the patient's status on the date of collection. Inpatient, registered outpatient, or non-patient. Pull the registration record, not the requisition, which is a question benefit verification should already have answered before the specimen moved.
2. Name the paragraph. Stored specimen, chemotherapy sensitivity, or molecular and ADLT. Write it down. The conditions you have to evidence follow from the paragraph.
3. Check the test is in scope. For the molecular exception, confirm the test is not performed by a blood bank or blood center, and check the current quarterly code list rather than a list someone saved two years ago.
4. Evidence each condition separately. The encounter record, the order date, the performance date, and a note that the result did not guide treatment during the encounter. Four artifacts, not one.
5. Set the date of service to the performance date and bill the Clinical Laboratory Fee Schedule. Hospitals billing non-patient laboratory tests use type of bill 14X, paid at the lesser of the actual charge, the fee schedule amount or the national limitation amount. Independent laboratories identify referred laboratory services with modifier 90.
6. Watch timely filing from the collection date, not the order date. A test held for an order that arrives on day 20 has already burned three weeks of the filing window.

That last point is not theoretical. Timely filing caused 6% of denials, and only 4% of those were recovered. In this category the clock starts long before anyone looks at the claim, which is why the order and the filing calendar belong in the same queue as the coding decision itself.

What is one month of this worth?

Take a reference laboratory running 40 hospital outpatient molecular tests a month that meet the five conditions in 414.510(b)(5).

A designated ADLT carries a median claim value of $2,940, a molecular pathology test $1,180, a cancer-related protein-based MAAA $810, and CPT 81490 $760. At the molecular pathology median, 40 qualifying tests are worth 40 times $1,180, or $47,200 a month.

Billed on the collection date instead, those 40 claims are not denied. They are never sent. The laboratory invoices the hospital at its contracted rate, the hospital packages the test into the outpatient payment it was already receiving, and $47,200 a month leaves the laboratory's Medicare book without ever appearing on a denial report. Across a year that is roughly $566,400, on tests that were performed, resulted and documented correctly.

The reverse error costs less but is more dangerous. Billing Medicare directly when the conditions were not met is a claim that should not have been submitted, and that is the version with an enforcement history attached.

Why do 14-day rule claims fail?

The ranked causes in the claims we audit put a routing error at the top, not a coding error.

Wrong billing party accounts for 31% of date of service errors, a date of service set to the collection date when an exception applied for 24%, a missing hospital outpatient encounter record for 18%, a non-patient treated as a hospital outpatient for 14%, an order held past the filing window for 8%, and a blood bank or blood center test claimed under the exception for 5%.

Work them in that order. Confirm patient status before you appeal anything, because if the patient was a non-patient the denial is correct and the appeal is wasted. Then confirm the encounter record exists, since a claim with no documented encounter is a resubmission with documentation rather than an appeal. Then confirm the performing laboratory is not a blood bank or blood center, which has been carved out of the exception since the CY2020 rule and still shows up on claims.

It is worth filing once you have sorted them. Appeals filed by Luxen were overturned 68% of the time, at a median appeal turnaround of 34 days from filing to payer decision. The larger problem is upstream of the appeal: 19% of denied claims were never reworked or appealed at all, and in this category the biggest losses are not denials in the first place. Ordering provider NPI was missing or invalid on 9% of lab claims, which is the kind of error that reaches the clearinghouse rather than the payer. Sorting a date of service queue into corrected claims, appeals and write-offs before anyone touches a payer portal is what a denials and AR queue is for.

Can you wait until day 14 to submit the order?

Not as a billing tactic, and this is the sharpest compliance line on the page.

In January 2025 the Department of Justice announced that Laboratory Corporation of America Holdings and related Labcorp entities, together with University Health System, agreed to pay $388,667 to resolve False Claims Act allegations. The alleged conduct, running from March 2012 to November 2023, was holding or resubmitting physician orders so they landed more than 14 days after discharge, which moved the date of service and let the test be billed separately to Medicare instead of to the hospital. The case was a qui tam action and the relator received $73,847.

The distinction the government is drawing is between clinical timing and billing timing. A physician who orders a test on day 18 because that is when the clinical question arose has produced a compliant claim. A workflow that parks orders until the calendar clears has produced a false one, and the documentation that proves which is which is the ordering record. Keep the order date, the clinical rationale and the discharge date in the same place, because that is the file an auditor asks for.

Did the 14-day rule change for 2026?

No. 42 CFR 414.510 has not been amended since the CY2021 OPPS final rule published on 29 December 2020, and the regulation text is current as of 1 October 2026. The CY2026 OPPS and ASC final rule contains no date of service provision, and the CY2026 Clinical Laboratory Fee Schedule annual update does not touch the policy either. Its changes are elsewhere: a CDLT data reporting period of 1 February to 30 April 2026, a phased payment reduction cap, a 1.9% annual update, and a national minimum payment of $18.54 for Pap smears.

What is moving is the pressure, not the rule. Cancer Precision Medicine Commons submitted comments to CMS on 10 June 2025 arguing that laboratories should be able to bill on the date of performance and that the billing guidance should be simplified. Separately, the RESULTS Act of 2025 is Clinical Laboratory Fee Schedule rate-setting reform effective in 2028 and does not address the date of service rule at all. Commentary that treats the two as the same thing is wrong, and it is worth checking before you build a 2026 workflow on it.

The practical reading for now: the rule you have to follow in 2026 is the rule as written in 2020, and the enforcement risk attached to it is more recent than the rule is.

Across 400 hospital outpatient molecular claims we reviewed, the laboratory billed Medicare on 214, the hospital bundled the test on 96, the wrong party billed on 68, and 22 were never billed by anyone. That last group is the one nobody finds, because an unsent claim produces no denial, no remittance and no entry in any report a laboratory reviews at month end. Counting them is the only way they surface, and that count is the first thing we run in a billing review.

Inpatient, outpatient or non-patient: who bills the test?

The patient's status at collection decides the answer before anything about the test itself matters. This is the grid we work from.

One line to carry out of the table: if there was no hospital encounter, there is no exception to claim, whatever the test is.

Laboratory

Reference and outreach laboratories carry the whole exposure here, because they are the party that either sends a Medicare claim or does not. The number worth producing monthly is the count of hospital outpatient specimens that met the five conditions against the count that produced a direct Medicare claim. In our review the gap was 68 claims in 400 billed by the wrong party and another 22 billed by nobody. If a laboratory cannot produce that reconciliation, the leak is unmeasured rather than absent. Building that count into the monthly close is ordinary laboratory revenue cycle work rather than a special project. The modifier and date of service mechanics sit alongside the rest of the laboratory billing ruleset.

Pathology

Anatomic pathology groups hit this where the technical and professional components split across two entities. The specimen was collected in a hospital procedure, the slides are read days later, and the natural but wrong instinct is to treat the read date as the date of service. It is not: under the general rule the date of service is the collection date, and only a named exception moves it. Groups running molecular alongside their routine case load end up applying two different paragraphs to specimens from the same patient, which is why pathology billing needs the paragraph recorded on the case rather than inferred later.

Oncology and infusion

Oncology is where the chemotherapy sensitivity exception at 414.510(b)(3) actually gets used, and where the molecular exception matters most in dollar terms because ADLTs cluster here. The timing question is clinical before it is financial: the 14-day count in that paragraph runs from the decision on chemotherapeutic agents, so the record that matters is the one documenting when and why that decision was made. Lapsed biologic re-authorizations caused 31% of GI infusion denials in our audit, and the same documentation discipline covers both problems.

Gastroenterology

GI practices generate stored specimens constantly, and the archived specimen rule bites here more than anywhere. A biopsy taken at a procedure, held, and sent for molecular testing four to six weeks later crosses the 30-day line, and at that point the date of service is the retrieval date rather than either the collection or the performance date. Pathology charges were billed a median of 11 days after the procedure in our billing reviews, so the storage clock is often already running before anyone in billing sees the case. The specialty picture is on our gastroenterology billing page.

Hospitals and health systems

The hospital is the party with the registration data that decides everything above, and usually the party with the least incentive to look. Two controls are worth owning: a report of outpatient specimens sent to outside laboratories with the encounter status attached, and a check on whether any ordering workflow introduces a delay that is not clinically driven. The second one is the control the Labcorp and University Health System settlement is really about. Where the hospital obtains tests under arrangements with an outside laboratory, only the hospital may bill for those services, so the arrangement itself has to match the date of service conclusion rather than contradict it.